Malignant gastrointestinal stromal tumor of the small intestine complicated with pulmonary tuberculosis during treatment with imatinib mesylate
M Takashima, N Igaki, T Matsuda, M Ohyama… - Internal …, 2005 - jstage.jst.go.jp
We describe a patient who had a metastatic gastrointestinal stromal tumor (GIST) after
previous failed extensive therapy, including multiple surgeries and hepatic artery …
previous failed extensive therapy, including multiple surgeries and hepatic artery …
Successful reintroduction of mesylate imatinib after pneumonitis in two patients with gastrointestinal stromal tumor (GIST)
N Izumiyama, K Noguchi, H Takahashi… - Nihon Kokyuki Gakkai …, 2009 - europepmc.org
We report 2 cases of successful reintroduction of mesylate imatinib for gastrointestinal
stromal tumor (GIST) after drug-induced pneumonitis. Both of them were women in the fifth …
stromal tumor (GIST) after drug-induced pneumonitis. Both of them were women in the fifth …
Imatinib induced severe skin reactions and neutropenia in a patient with gastrointestinal stromal tumor
JE Hwang, JY Yoon, WK Bae, HJ Shim, SH Cho… - BMC cancer, 2010 - Springer
Background Imatinib mesylate has been used for the treatment of unresectable or metastatic
gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 …
gastrointestinal stromal tumors (GIST). The current recommended dose of imatinib is 400 …
Peritoneal tuberculosis after imatinib therapy
L Senn, T Kovacsovics, PE Tarr… - Archives of Internal …, 2009 - jamanetwork.com
Imatinib mesylate, a selective inhibitor of the BCR-ABL tyrosine kinase gene, is now a
standard therapy in patients with chronic myeloid leukemia (CML) and gastrointestinal …
standard therapy in patients with chronic myeloid leukemia (CML) and gastrointestinal …
Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour …
C Högenauer, C Langner, RW Lipp… - European journal of …, 2003 - journals.lww.com
We report a 51-year-old man with an advanced malignant metastatic gastrointestinal stromal
tumour, who showed a complete response after 5 months of treatment with imatinib at a …
tumour, who showed a complete response after 5 months of treatment with imatinib at a …
Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
T Wakai, T Kanda, S Hirota, A Ohashi, Y Shirai… - British Journal of …, 2004 - nature.com
Currently, there are no data on the secondary resistance of gastrointestinal stromal tumours
to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed …
to imatinib. Here, we report a case of metastatic gastrointestinal stromal tumour that relapsed …
Secondary c-kit Mutation in a Recurrent Gastrointestinal Stromal Tumor Under Long-Term Treatment with Imatinib Mesylate: Report of a Case
T Utsunomiya, M Okamoto, S Yano, T Kameyama… - Surgery today, 2008 - Springer
Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the c-kit
receptor gene, which are targets for imatinib mesylate. However, imatinib resistance is an …
receptor gene, which are targets for imatinib mesylate. However, imatinib resistance is an …
An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient
S Aliberti, G Grignani, P Allione, M Fizzotti… - American journal of …, 2009 - journals.lww.com
A65-year-old man was admitted to our hospital with a 6-month history of increasing
abdominal size. His medical history was unremarkable. On physical examination, a mass …
abdominal size. His medical history was unremarkable. On physical examination, a mass …
Drug-induced pneumonia that may have been caused by imatinib mesylate administered for gastrointestinal stromal tumor
E Iritani, M Kondo, T Kanemura, Y Hara… - Nihon Kokyuki Gakkai …, 2007 - europepmc.org
The patient was a 64-year-old woman who had undergone partial enterectomy for a small
intestinal tumor in August 2005, and gastrointestinal stromal tumor (GIST) was diagnosed …
intestinal tumor in August 2005, and gastrointestinal stromal tumor (GIST) was diagnosed …
Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
AAP Ghias, S Bhayani, DJ Gemmel… - Journal of Community …, 2018 - Taylor & Francis
Gastrointestinal stromal tumors (GISTs) are rare and current estimates range from 4,000 to
6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has …
6,000 number of GIST cases in the USA annually. Imatinib, a tyrosine kinase inhibitor, has …